CELC - Celcuity Inc.
On Thursday, Celcuity Inc. (NASDAQ:CELC) announced amendments to its Phase 3 VIKTORIA-2 clinical trial evaluating gedatolisib as a first-line treatment for patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
Celcuity Inc. (CELC) Q1 2026 Earnings Call Transcript
Celcuity NASDAQ: CELC reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its investigational therapy for hormone receptor-positive, HER2-negative advanced breast cancer.
MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced financial results for the first quarter ended March 31, 2026 and other recent business developments.
Development of a gedatolisib formulation for subcutaneous injection is underway; first patent application submitted to the U.S. Patent and Trademark Office Development of a gedatolisib formulation for subcutaneous injection is underway; first patent application submitted to the U.S. Patent and Trademark Office
MINNEAPOLIS, May 07, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2026 after the market closes on Thursday, May 14, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m.
Celcuity Inc. (NASDAQ:CELC) shares are up during Monday's premarket session following positive news about its Phase 3 VIKTORIA-1 trial results.
Detailed data for the gedatolisib triplet and doublet regimens will be presented at a late-breaking abstract oral session at the 2026 ASCO Annual Meeting Detailed data for the gedatolisib triplet and doublet regimens will be presented at a late-breaking abstract oral session at the 2026 ASCO Annual Meeting
Celcuity (CELC) is rated a cautious Buy, with upside contingent on positive mutant cohort data for gedatolisib in 2L HR+/HER2- advanced breast cancer. Current $6B valuation already prices in significant success, assuming $1–1.5B peak sales; management's $2.5B target requires broad label and strong market adoption. VIKTORIA-1 phase 3 data show gedatolisib offers best-in-class efficacy and manageable safety in wild-type patients, but mutant cohort results in Q2 2026 are the key catalyst.
An analyst initiated coverage of the biotech.
Nisa Investment Advisors LLC lowered its stake in shares of Celcuity, Inc. (NASDAQ: CELC) by 96.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 508 shares of the company's stock after selling 15,119 shares during the period. Nisa
It very much surprised on the upside on the bottom-line result. It also has a much longer cash runway than it did at the end of 2024.
Celcuity Inc. (CELC) Q4 2025 Earnings Call Transcript
MINNEAPOLIS, March 25, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced financial results for the fourth quarter and full year ended December 31, 2025, and other recent business developments.
MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2025 after the market closes on Wednesday, March 25, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m.
Shares of Celcuity, Inc. (NASDAQ: CELC - Get Free Report) have received an average rating of "Moderate Buy" from the ten research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have given a buy recommendation to the
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.
Celcuity Inc. (CELC) Presents at Leerink Global Healthcare Conference 2026 Transcript
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology and strategic licensing in oncology.
MINNEAPOLIS, March 09, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced publication of efficacy and safety results from the PIK3CA wild-type (“WT”) cohort of the Phase 3 VIKTORIA-1 clinical trial of gedatolisib, an investigational pan-PI3K/mTORC1/2 inhibitor, in the Journal of Clinical Oncology. The cohort consists of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”) PIK3CA WT advanced breast cancer (“ABC”), following progression on or after treatment with a CDK4/6 inhibitor and an aromatase inhibitor.